FT4/FT3 ratio: A novel biomarker predicts coronary microvascular dysfunction (CMD) in euthyroid INOCA patients

Han Zhang1,2†, Wenliang Che3†, Kuangyu Shi4,5†, Yan Huang1,2, Chong Xu3, Mengyu Fei6, Xin Fan1,2, Jiajia Zhang1,2, Xueping Hu1,2, Fan Hu1,2, Shanshan Qin1,2, Xiaoying Zhang1,2, Qingqing Huang* and Fei Yu1,7*

1Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 2Institute of Nuclear Medicine, Tongji University School of Medicine, Shanghai, China, 3Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 4Department of Nuclear Medicine, University of Bern, Bern, Switzerland, 5Department of Informatics, Technical University of Munich, Munich, Germany, 6Department of Radiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 7Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

Background: Ischemia and no obstructive coronary artery disease (INOCA) patients who presented coronary microvascular dysfunction (CMD) demonstrate a poor prognosis, yet the risk factors for CMD remain unclear. Subtle changes in thyroid hormone levels within the normal range, especially the free thyroxine (FT4)/free triiodothyronine (FT3) ratio, have been shown to regulate the cardiovascular system. This prospective study investigated the correlation between FT4/FT3 ratio and CMD in euthyroid patients with INOCA.

Methods: This prospective study (www.chictr.org.cn/, ChiCTR2000037112) recruited patients with myocardial ischemia symptoms who underwent both coronary angiography (CAG) and myocardial perfusion imaging (MPI) with dynamic single-photon emission computed tomography (D-SPECT). INOCA was defined as coronary stenosis< 50% and CMD was defined as coronary flow reserve (CFR)<2.5. All patients were excluded from abnormal thyroid function and thyroid disease history.

Results: Among 71 INOCA patients (15 [21.1%] CMD), FT4 and FT4/FT3 ratio in CMD group were significantly higher and both showed significantly moderate correlation with CFR (r=-0.25, p=0.03; r=-0.34, p=0.003, respectively). The ROC curve revealed that FT4/FT3 ratio had the highest efficacy for predicting CMD with an optimized cutoff value>3.39 (AUC 0.78, p<0.001, sensitivity, 80.0%; specificity, 71.4%). Multivariate logistic regression showed that FT4/FT3 ratio was an independent predictor of CMD (OR 7.62, 95% CI 1.12-51.89, p=0.038, P for trend=0.006).
Conclusion: In euthyroid INOCA patients, increased FT4/FT3 ratio levels are associated with the occurrence of CMD, presenting a novel biomarker for improving the risk stratification.

KEYWORDS
INOCA, CMD, thyroid hormone, D-SPECT, CFR

Introduction

More than 50% of patients with myocardial ischemia symptoms who underwent coronary angiography (CAG) did not find an obstructive lesion (coronary stenosis >50%), and these patients are now diagnosed with ischemia and no obstructive coronary artery disease (INOCA) (1, 2). It was once considered a benign disease, conversely, recent studies have shown that this group of patients has a high rate of mortality and adverse clinical outcomes (3). Coronary microvascular dysfunction (CMD) is one putative mechanism leading to INOCA (4), defined as the spectrum of structural and functional alterations at the level of epicardial, microvascular endothelial that limits myocardial perfusion, which is most often detected as the reduction of coronary flow reserve (CFR) (5, 6). Meanwhile, contemporary studies have suggested that the presence of CMD in INOCA patients further increases the risk of adverse events (7, 8). Nevertheless, the risk factors for CMD in INOCA patients are still unclear.

The effects of abnormal thyroid hormone levels on the cardiovascular system have been well demonstrated (9, 10). Since the widespread presence of thyroid hormone receptors in myocardial tissue, subtle changes in thyroid hormone levels within the reference range can also cause deregulation of the cardiovascular system and have shown a similarly strong connection with cardiovascular risk factors (11). In particular, the higher free thyroxine (FT4)/free triiodothyronine (FT3) ratio reflects the decrease in tissue-specific deiodinase activity and was demonstrated as a novel biological marker to predict the prognosis of several cardiovascular diseases (12, 13), which led us to hypothesize that this ratio would also probably relevant with CMD in euthyroid INOCA patients.

The current gold standard for noninvasive assessment of CFR is positron emission tomography (PET) myocardial absolute blood flow measurement (14, 15). Due to the restrictions in scanning equipment and costs, using dynamic cardiac SPECT (D-SPECT) to estimate CFR has been gradually applied in clinical practice and has been validated to maintain a good agreement with PET (16–18). Therefore, this study was designed as a prospective trial to assess the potential correlation between FT4/FT3 ratio and D-SPECT derived CFR, while determining whether it is an independent risk factor for CMD in euthyroid INOCA patients to further improve the risk stratification.

Materials and methods

Study population

In this prospective study, we recruited 150 patients with myocardial ischemia symptoms who underwent both CAG and D-SPECT CFR within two days in Shanghai Tenth people’s hospital from 2020 to 2021. After excluding the previous history of myocardial infarction or coronary revascularization, 87 patients who present non-obstructive coronary stenosis (<50%) were diagnosed as INOCA. Further biochemical examinations excluded 16 patients: Hyperthyroidism (n=4); Hypothyroidism (n=6); Subclinical hypothyroidism (n=2); Hashimoto’s thyroiditis (n=4). A total of 71 euthyroid INOCA patients were included in the final study cohort. We divided them into two groups (1): the CMD group (CFR<2.5), and (2) non-CMD group (CFR≥2.5). The patient flowchart is shown in Figure 1.

Biochemical assessment

Fasting blood was obtained to test thyroid hormone levels [including free triiodothyronine (FT3), free tetraiodothyronine (FT4), total triiodothyronine (TT3), total tetraiodothyronine (TT4), thyroid stimulating hormone (TSH), thyroglobulin autoantibodies (TGA)], thyroid peroxidase antibody (TPOAb), thyroid receptor antibodies (TRAb)].

Thyroid function profile was measured by direct chemiluminescence method (ADVIA Centaur XP, Siemens, USA). The reference intervals were as follows: FT3:2.8-6.3pmol/L, FT4:10.5-24.4pmol/L, TT3:1.0-3.0nmol/L, TT4:55.5-161.3nmol/L, TSH:0.38-4.34pmol/L, TGA<110IU/ml, TPOAb<40IU/ml, TRAb<1.75IU/L.

Dynamic SPECT acquisition

All patients underwent a one-day rest-stress dynamic and conventional acquisition on D-SPECT (Spectrum Dynamics
Medical Ltd., Israel, Caesarea, Serial Number: 5217). Stop taking β-blockers, theophylline, dipyridamole, and ACEI drugs for at least 12 h before examination. All scans were performed after overnight fasting.

For rest imaging, an initial dose of approximately 37 MBq (1 mCi) is required to position the patient’s heart within the field of view and to establish the scanning ROI. The remaining dose of approximately 370 MBq (10 mCi) is then injected into the patient, and the rest dynamic images were acquired by list mode for over 6 min. After a 60-90 min delay, rest perfusion scanning was performed.

For stress imaging, no positioning dose is required as the heart location can be identified from the resting activity. Pharmacological stress agent ATP was instilled at a rate of 140 ug/(kg·min) through the venous access and 925 MBq (25 mCi) MIBI was injected 3 min after the start of ATP injection. Then stress dynamic images were acquired in list mode over 6 min. After a 60-90 min delay, stress perfusion scanning was performed. The dynamic imaging protocol is illustrated in Figure 2.

Dynamic SPECT analysis

Dynamic imaging data is re-binned into 32 frames consisting of 3 sec x 21 frames, 9 sec x 1 frame, 15 sec x 1 frame, 21 sec x 1 frame, 27 sec x 1 frame, and 30 sec x 7 frames. An OSEM technique is used for the reconstruction of dynamic imaging acquisitions, with 4 iterations and 32 subsets. All dynamic data and corresponding perfusion information are analyzed using semi-quantitative methods in Corridor 4DM software (INVIA, Ann Arbor, MI, USA). Left ventricular (LV) endocardial and epicardial surfaces are algorithmically estimated from summed myocardial images beyond the two-minute mark. A midwall surface, determined equally distant between the endocardial and epicardial surfaces, is divided into 460 polar map sectors, where LV myocardial tissue time-activity curves (TAC) are the nearest neighbor sampled at the center of each sector across all time frames. The CFR analysis makes use of ROI blood sampling by averaging a box-shaped region in the LV blood pool, specifically in the center of the LV on the short axis and centered at the basal valve plane along the long-axis, across

FIGURE 2
D-SPECT MPI-CFR workflow.
all time frames. The size of the ROI is two pixels wide on the short axis and 30mm long on the long-axis to sample both the LV and left atrial cavities. The Myocardial blood flow (MBF) was estimated through the previously established net retention model (19) and CFR was calculated as the ratio of the stress MBF to the rest MBF.

Statistics analysis

Continuous data were presented as mean ± standard deviation, and categorical data were presented as frequency and percentage. The 2 test was used for categorical data. Independent samples t-test was used to compare the means of continuous variables between the CMD group and non-CMD group. The receiver operating characteristic curve (ROC) was performed to calculate the best cut-off value of thyroid hormone for CMD prediction. Pearson’s correlation was used to clarify the relationship between thyroid hormone and CFR. The least absolute shrinkage and selection operator (LASSO) regression was used to select the variables that entered into multivariate logistic regression. Multivariable logistic regression analysis was used to explore the association between FT4/FT3 ratio and CMD while controlling for potential confounders. Results were presented as odds ratio (OR) and 95% confidence interval (95% CI). A two-sided P value of < 0.05 was considered significant. All statistical analysis were performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA) and MedCalc 18.0.

Results

Baseline characteristics

A total of 71 INOCA patients (mean age 63.2 ± 9.3 years; 36 [50.7%] male) were included in this prospective study. Baseline characteristics, cardiovascular risk factors, and followed medications were compared in Table 1. With the CFR cut-off value < 2.5, 15 [21.1%] patients were presented CMD and was significantly older than the non-CMD group (68.6 ± 8.0 vs 61.8 ± 9.1, p=0.01). Meanwhile, the proportion of 2 vessel disease was higher in the CMD group (33.3% vs 10.7%, p=0.04) and no patients with 3 vessel disease in either group.

Thyroid hormone levels, resting/stressing myocardial blood flow, and global CFR was illustrated in Table 2. FT4 (16.90 ± 1.36 vs 15.55 ± 2.00, p=0.02) and FT4/FT3 ratio (3.61 ± 0.37 vs 3.16 ± 0.44, p<0.001) were significantly higher in the CMD group. The differences between other thyroid hormones were not statistically significant and were shown in Figure 3. As expected, the Stress MBF (2.82 ± 0.95 vs 4.34 ± 1.23, p=0.002) and CFR (2.00 ± 0.34 vs 3.62 ± 0.95, p<0.001) were significantly lower than non-CMD group.

Correlation between thyroid hormones and CFR

As depicted in the Figure 4, both FT4 and FT4/FT3 ratio showed a modest significant correlation with CFR (r=-0.25, p=0.03; r=-0.34, p=0.003, respective). ROC curve analysis was used to identify the relative intensity of the association between FT4, FT4/FT3 ratio and CFR. FT4/FT3 ratio had highest AUC 0.78 (95%CI 0.67-0.87, p<0.001), which was larger than that for FT4 (AUC 0.71, 95%CI 0.60-0.82, p<0.001). Using Youden’s index to calculate the best cut-off value for FT4/FT3 ratio was >3.39 (sensitivity 80.0% and specificity 71.4%) and FT4 was >15.42 (sensitivity 93.3% and specificity 55.4%). All results are summarized in Figure 5.

Risk factors of CMD

As shown in Figure 6, a total of 19 relevant clinical variables (including chronic medical history, thyroid hormones, and cardiovascular-related biochemicals), 3 potential features were selected with nonzero coefficients in the LASSO regression model (FT4, FT4/FT3 ratio and age). After including the above three variables into multivariate regression, the results indicate that FT4/FT3 ratio (OR 7.62, 95% CI 1.12-51.89, p=0.038) and age (OR 1.09, 95% CI 1.00-1.19, p=0.037) still were independent predictors of CMD in INOCA patients. The results of multivariate logistic regression are demonstrated in Table 3. The FT4/FT3 ratio and age were further trisection into 3 groups for trend testing. As shown in Table 4, with Q1 set as the reference, the FT4/FT3 ratio (OR 14.79, 95% CI 1.69-129.52, P for trend=0.006) and age (OR 7.08, 95% CI 1.30-38.44, P for trend=0.02) in Q3 were both associated with an increased risk for CMD.

Discussion

Our study has the following three main findings. Firstly, FT4 and FT4/FT3 ratio levels were higher in CMD patients; secondly, both FT4 and FT4/FT3 ratios were correlated with CFR; finally, it was demonstrated that the increased FT4/FT3 ratio predicted the risk of CMD in euthyroid INOCA patients, which provide a novel biological marker to improving risk stratification.

Baseline characteristic

CMD plays a pivotal role in INOCA patients, which is considered to be the third mechanism causing myocardial ischemia in addition to coronary atherosclerosis and vasospasm.
## TABLE 1 Clinical characteristics of the study population (n = 71).

|                         | Total (n=71) | Non-CMD (n=56) | CMD (n=15) | P value |
|-------------------------|--------------|----------------|------------|---------|
| **Patient characteristics** |              |                |            |         |
| Age, years              | 63.21 ± 9.28 | 61.77 ± 9.13   | 68.60 ± 7.98 | 0.01*   |
| Male gender, n (%)      | 36 (50.7%)   | 28 (51.8%)     | 7 (46.7%)  | 0.72    |
| Height, cm              | 167.26 ± 8.81| 166.79 ± 9.02 | 168.86 ± 8.19 | 0.44    |
| Weight, Kg              | 71.63 ± 12.05| 70.70 ± 12.03  | 74.86 ± 11.96 | 0.26    |
| Body mass index, km²    | 25.49 ± 3.28 | 25.29 ± 3.37   | 26.15 ± 2.99 | 0.40    |
| Hypertension, n (%)     | 45 (63.4%)   | 33 (58.9%)     | 12 (80.0%)  | 0.13    |
| Diabetes, n (%)         | 10 (14.1%)   | 9 (16.1%)      | 1 (6.7%)   | 0.68    |
| Dyslipidaemia, n (%)    | 6 (8.5%)     | 5 (8.9%)       | 1 (6.7%)   | 1       |
| Current Smoker, n (%)   | 13 (18.3%)   | 11 (19.6%)     | 2 (13.3%)  | 0.72    |
| HDL, mmol/L             | 1.14 ± 0.28  | 1.14 ± 0.26    | 1.14 ± 0.34 | 0.97    |
| LDL, mmol/L             | 2.47 ± 0.76  | 2.48 ± 0.80    | 2.44 ± 0.58 | 0.86    |
| Cholesterol, mmol/L     | 4.20 ± 0.87  | 4.23 ± 0.90    | 4.12 ± 0.76 | 0.69    |
| Triglycerides, mmol/L   | 1.73 ± 1.23  | 1.78 ± 1.35    | 1.54 ± 0.68 | 0.50    |
| Glomerular filtration rate | 87.55 ± 15.05 | 89.16 ± 14.60 | 82.04 ± 15.83 | 0.12    |
| **Baseline Medications** |              |                |            |         |
| Aspirin, n (%)          | 22 (31.0%)   | 16 (28.6%)     | 6 (40%)    | 0.53    |
| Statins, n (%)          | 54 (76.1%)   | 44 (78.6%)     | 10 (66.7%) | 0.33    |
| Beta-blockers, n (%)    | 24 (33.8%)   | 21 (37.5%)     | 3 (20%)    | 0.20    |
| CCB, n (%)              | 20 (28.2%)   | 14 (25.0%)     | 6 (40.0%)  | 0.33    |
| ACEI or ARB, n (%)      | 20 (28.2%)   | 17 (30.4%)     | 3 (20.0%)  | 0.53    |
| Nitrate, n (%)          | 8 (11.3%)    | 6 (10.7%)      | 2 (13.3%)  | 0.67    |
| **Angiographic findings** |              |                |            |         |
| LAD                      | 40           | 34             | 6          |         |
| LCX                      | 3            | 3              | 0          |         |
| RCA                      | 16           | 8              | 8          |         |
| 0-vessel, n (%)          | 23 (37.7%)   | 17 (30.3%)     | 6 (40.0%)  | 0.63    |
| 1-vessel, n (%)          | 37 (52.1%)   | 33 (58.9%)     | 4 (26.7%)  | 0.009*  |
| 2-vessels, n (%)         | 11 (15.5%)   | 6 (10.7%)      | 5 (33.3%)  | 0.04*   |
| 3-vessels, n (%)         | 0 (0.0%)     | 0 (0.0%)       | 0 (0.0%)   |         |

* Represent P < 0.05.

## TABLE 2 Thyroid hormone level and CFR of the study population.

|                         | Total (n=71) | Non-CMD (n=56) | CMD (n=15) | P value |
|-------------------------|--------------|----------------|------------|---------|
| **Thyroid hormone level** |              |                |            |         |
| FT3, pmol/L             | 4.90 ± 0.55  | 4.96 ± 0.58    | 4.71 ± 0.40 | 0.13    |
| FT4, pmol/L             | 15.83 ± 1.95 | 15.55 ± 2.00   | 16.90 ± 1.36 | 0.02*   |
| TT3, nmol/L             | 1.58 ± 0.27  | 1.61 ± 0.27    | 1.49 ± 0.25 | 0.11    |
| TT4, nmol/L             | 96.55 ± 17.14| 95.09 ± 15.41  | 101.87 ± 22.20 | 0.18    |
| TSH, mIU/L              | 2.13 ± 0.92  | 2.15 ± 0.90    | 2.07 ± 1.02 | 0.85    |
| FT4/FT3 ratio           | 3.25 ± 0.46  | 3.16 ± 0.44    | 3.61 ± 0.37 | 0.001*  |
| **Myocardial Blood Flow** |              |                |            |         |
| Stress MBF, ml/min/g    | 4.07 ± 1.31  | 4.34 ± 1.23    | 2.82 ± 0.95 | 0.002*  |
| Rest MBF, ml/min/g      | 1.29 ± 0.49  | 1.27 ± 0.50    | 1.25 ± 0.46 | 0.54    |
| CFR                     | 3.27 ± 1.08  | 3.62 ± 0.95    | 2.00 ± 0.34 | <0.001* |

* Represent P < 0.05.
Since there is no severe stenosis in the epicardial coronary arteries, the CFR truly reflects the microvascular function of INOCA patients. In our present study, 21.1% of INOCA patients presented with CMD, slightly lower than reported in previous research (22), probably because we excluded some INOCA patients with abnormal thyroid function. Meanwhile, the higher proportion of patients with 2-vessels stenosis also considerably explains the decrease in CFR in the CMD group. Notably, although CMD has been shown to be common complication of type 2 diabetes mellitus (T2DM) (23–27), differences between the two groups did not significantly due to our small sample size. Meanwhile, other traditional cardiovascular risk factors such as hypertension, hyperlipidemia, and smoking in this study also appeared similarly due to the sample size.

Clinical predictors

Previous studies have established a strong association between abnormal thyroid hormones and increased cardiovascular risk (9). To our knowledge, our study is the first prospective cohort on the relationship between thyroid function in the reference range and CMD risk. Although not a biological hormone directly involved in the regulation of the cardiovascular system, our results suggest that the FT4/FT3 ratio, and not FT4, is an independent risk factor for CMD. Since the affinity of thyroid hormone receptors for T3 is tenfold higher than that of T4, the endocrine system tends to convert T4 to T3 for biological activity, while the FT4/FT3 ratio reflects this dynamic conversion process and is considered the surrogate for evaluating the degree of peripheral thyroxine deiodination and deiodinase activity (9). Similar to our research, recent studies have shown that an elevated FT4/FT3 ratio is associated with adverse prognosis in a variety of cardiovascular diseases. Yuan. et al retrospectively analyzed 3549 euthyroid patients with prior cardiovascular events history undergoing PCI and confirmed that an increased FT4/FT3 ratio predicts all-cause death and cardiac death (28). Meanwhile, for another coronary artery disease in which CMD is involved in the pathogenesis, Gao. et al. found that a lower level of FT3/FT4 ratio remained a robust predictor of MACE in euthyroid MINOCA patients (29). When we focus on non-cardiac disease...
FIGURE 4
Correlation between thyroid hormone (A) FT3 (B) FT4 (C) TSH (D) FT4/FT3 ratio and CFR. Correlation coefficients (r) and P values are shown.

FIGURE 5
ROC curves of (A) FT4 and (B) FT4/FT3 ratio in predicting CMD. Cutoff value and corresponding sensitivity and specificity are shown. ROC, receiver operating characteristic; AUC, area under the curve.
studies, high levels of FT4/FT4 ratio still represent the worsening illness condition. Maruzzo. et al. performed a prognostic follow-up analysis with 134 mRCC patients, results showed that the low FT3/FT4 ratio independently predict progression-free survival (PFS) and overall survival (OS) (30).

Our results also showed that FT4 was elevated in CMD patients and increased FT4 levels were correlated with decreased CFR. Although T4 requires conversion to T3 to exert its powerful biological effects, increased FT4 levels can still act directly on thyroid hormone receptors in a variety of tissues to promote excessive NO release from endothelial cells, exaggerated coronary vascular tone, and subsequently leading to endothelial dysfunction (10). Similarly, The recently systematic review involving 11 studies with 30,085 patients showed that elevated FT4 levels within the normal range were associated with the incidence of atrial fibrillation (11). Moreover, Anne R. et al. demonstrated that, in addition to an increased risk of atrial fibrillation, high levels of FT4 were also strongly associated with heart failure and mortality (31). Nevertheless, ROC analysis indicated that the FT4/FT3 ratio was the most effective biomarker in predicting CMD, which suggests that we should focus more on the dynamics of thyroid hormone metabolism rather than a particular thyroid hormone.

Another important finding indicated that age was higher in the CMD group and advancing age was significantly associated with the increased CMD risk. These results may be explained by the fact that aging impairs endothelium-mediated coronary vasodilation and angiogenesis, which in turn promotes structural remodeling of the microvasculature and subsequently leads to reduced perfusion of the microcirculation (32, 33). Similar findings have been reported in a cohort with 327 IHD patients and 419 stenosed vessels, the progressive decrease in CFR in both obstructed and non-obstructed coronary arteries was age-related (34). Of note, through altering the phenotype of endothelial cells and smooth muscle cells, microvascular aging also negatively affects the function of the endocrine system in regulating thyroid hormones (35). Strich et al. found that age affects the T4 to the T3 conversion process, older patients are usually accompanied by an elevated FT4/FT3 ratio (36).

The CMD group in our research likewise had a higher age and FT4/FT3 ratio, a possible explanation for this might be that increased age leads to decreased metabolism, further leads to reduced deiodinase activity, and more conversion of T4 to reverseT3 (rT3) rather than T3.

**Limitations**

This study has several limitations. First, since this study is a single-center prospective study, further sample size expansion and multicenter validation are needed. Second, we require additional

| Variables after LASSO regression | OR (95%CI) | P value |
|----------------------------------|-----------|---------|
| Age, years                       | 1.09 (1.00-1.19) | 0.037* |
| FT4/FT3 ratio                    | 7.62 (1.12-51.89) | 0.038* |
| FT4                              | 1.22 (0.81-1.85)  | 0.34    |

* Represent P < 0.05
follow-up data for this group of patients to clarify the prediction of major adverse cardiovascular events by FT4/FT3 ratio. And some new biological cardiac functional markers associated with thyroid function, such as Brain natriuretic peptide (BNP) (37), could be added in further study to make our results more reliable. Finally, we need to explore the correlation between the FT4/FT3 ratio with different clinical classifications of CMD.

**Conclusion**

Taken over, increased FT4/FT3 ratio is strongly consistent with an increased risk of CMD, the high predictive efficacy for CMD is expected to provide a novel biomarker for early prevention and risk stratification in euthyroid INOCA patients.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**Ethics statement**

The studies involving human participants were reviewed and approved by Shanghai Tenth people’s hospital ethics committee. The patients/participants provided their written informed consent to participate in this study.

**Author contributions**

FY, QH: conception and design. HZ, WC and YH: data collection and analysis. KS: Language editing and polishing. CX, XF, MF, SQ and XH: data curation. JZ, FH and XZ: Provision of study materials. All authors contributed to the article and approved the submitted version.

**Funding**

The study was supported by research grants from the National Key Research and Development Program of China (2020YFA0909000), The National Natural Science Foundation of China (82127807), Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), Clinical Research Plan of SHDC (2020CR4065) and The National Natural Science Foundation of China (No.82071956).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.1021326/full#supplementary-material

### Table 4 Logistic regression analysis for predicting CMD according to trisection of predictors.

| Predictors | No. of cases | OR    | 95% CI       |
|------------|--------------|-------|--------------|
| FT4/FT3 ratio |              |       |              |
| Q1 (<3.080) | 24           | 1.00  |              |
| Q2 (3.080-3.456) | 24          | 6.05  | 0.65-56.36   |
| Q3 (>3.456) | 23           | 14.79 | 1.69-129.52  |
| P for trend |              | 0.006*|              |
| Age (years) |              |       |              |
| Q1 (<59) | 25           | 1.00  |              |
| Q2 (59-66) | 25           | 2.87  | 0.50-16.48   |
| Q3 (>66) | 21           | 7.08  | 1.30-38.44   |
| P for trend |              | 0.02* |              |

* Represent P < 0.05.
References

1. Bairer M, GR, P. M, W, N, et al. Ischemia and no obstructive coronary artery disease (INOCA). Developing evidence-based therapies and research agenda for the next decade. Circulation (2017) 135:1075-92. doi: 10.1161/CIRCULATIONAHA.116.024534

2. Beltrame JF, Tavella R, Jones D, Zeitz C. Management of ischaemia with non-obstructive coronary arteries (INOCA). BMJ (2021) 375:e600602. doi: 10.1136/bmj-2021-060602

3. Radioco F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Iopesper L, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary disease: a systematic review and meta-analysis. Eur Heart J (2018) 39:2135–46. doi: 10.1093/eurheartj/ehy385

4. Reynolds HR, Picard MH, Petrus J, Lopez Sendon JL, Senior R, et al. Natural history of patients with ischemia and no obstructive coronary artery disease: The CIAO-ISCHEMIA study. Circulation (2021) 144:1008–23. doi: 10.1161/CIRCULATIONAHA.120.046791

5. Kasli I-C, Cree F, Grebil B, Camici PG. Reappraisal of ischemic heart disease: Fundamental role of coronary microvascular dysfunction in the pathogenesis of angina pectoris. Circulation (2018) 138:1483–80. doi: 10.1161/CIRCULATIONAHA.118.031373

6. Sodhi I, Brown D, Gede S, Lanza GA, Shimokawa H, Sidki N. Non-collateral microvascular dysfunction in stable ischemic heart disease (non-collateral coronary artery disease and obstructive coronary artery disease). Cardiovasc Res (2020) 110:772–86. doi: 10.1093/cvr/cvaa005

7. Huserovic R, Sedlak T, Wei J, Peipp J, Handberg E, Bairer M. Ischemia and no obstructive coronary artery disease (INOCA): What is the risk? JAMA Oncol (2018) 4:e008868. doi: 10.1001/jamaoncol.2018.008868

8. Pepple CJ, Anderson RD, Sharaf BL, Paik MJ, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcomes in women evaluated for suspected ischemia. J Am Coll Cardiol (2010) 55:2825–32. doi: 10.1016/j.jacc.2010.01.054

9. Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol (2017) 14:39–55. doi: 10.1038/nrcardio.2016.174

10. Irwin K, Kaie O. Thyroid hormone and the cardiovascular system. N Engl J Med (2001) 344:751–9. doi: 10.1056/NEJMe2010013440077

11. Baumann C, della Costa BR, Collet T-H, Feller M, Florianis C, Bauer DC, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation (2017) 136:2100–16. doi: 10.1161/CIRCULATIONAHA.117.028753

12. Pasqualetti G, Calosolvo G, Bernardini S, Linsalata G, Bigazzi R, Caraccio N, et al. Degree of peripheral thyroxin deiodination, frailty, and long-term survival in coronary artery disease and obstructive coronary artery disease. J Atheroscler Thromb (2020) 26:1020–32. doi: 10.5558/jat.2019007

13. Le TN, Celi FS, Wickham EP. Thyrotropin levels are associated with atrial fibrillation. J Clin Endocrinol Metab (2014) 100:1088–90. doi: 10.1210/jc.2014-3586

14. Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez Sendon JL, Senior R, et al. Functional and economic impact of INOCA and in non-obstructive coronary artery disease: The CIAO-ISCHEMIA study. J Clin Endocrinol Metab (2020) 106:1525–34. doi: 10.1210/jc.2020-00475

15. Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, Dato C, et al. PDES inhibition ameliorates visceral adiposity targeting the mR2-SIRT1 pathway: Evidence from the CRECISED trial. J Clin Endocrinol Metab (2021) 106:1525–34. doi: 10.1210/jc.2020-00475

16. Venneri MA, Barbagallo F, Fiore D, De Gaetano R, Giannetta E, Sbardella E, et al. PDES inhibition stimulates Tie2-expressing monocytes and angiopoietin-1 restoring angiogenic homeostasis in diabetes. J Clin Endocrinol Metab (2019) 104:2623–36. doi: 10.1210/jc.2018-02525

17. Reznik M, van Ark J-L, Lesin CPH, Visser LM, Lodewijk ME, van der Horst ICC, et al. Increased frequency of proangiogenic tunica intima endothelial kinase 2 (Tie2) expressing monocytes in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol (2020) 19:27–32. doi: 10.1186/s12933-020-00497-6

18. Poiz R, Giannetta E, Galea N, Fraccone M, Campo Foo, Barbagallo F, et al. Diabetic cardiomyopathy progression is triggered by miR122-5p and involves extracellular matrix. JACC Cardiovasc Imaging (2021) 14:1130–42. doi: 10.1016/j.jcmg.2020.11.009

19. Poiz R, Giannetta E, Feola T, Galea N, Barbagallo F, Campo Foo, et al. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOVER, a randomized, double-blind, placebo-controlled trial. Circ Transl Med (2022) 14:888503. doi: 10.1126/scitranslmed.abb503

20. Yuan D, Jia S, Zhu P, Zhang C, Liu Y, Liu R, et al. Usefulness of FT3 to FT4 ratio to predict mortality in euthyroid patients with prior cardiovascular events undergoing PCI. Five-year findings from a large single-center cohort study. Front Endocrinol (2021) 12:700349. doi: 10.3389/fendo.2021.700349

21. Gao S, Ma W, Huang S, Lin X, Yu M. Predictive value of free triiodothyronine to free thyroxine ratio in euthyroid patients with myocardial infarction with nonobstructive coronary arteries. Front Endocrinol (2021) 12:708216. doi: 10.3389/fendo.2021.708216

22. Maruzzo M, Verzoni E, Vitale MG, Diomese N, Buti S, Galli L, et al. Prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: Results from the threefour study (Meet-URO 140). Front Oncol (2017) 7:11878385. doi: 10.3389/fonc.2017.787835

23. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Pauly BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab (2015) 100:1098–96. doi: 10.1210/jc.2014-3586

24. Ungvari Z, Tarantini S, Sorond F, Merkley B, Ciszar A. Mechanisms of vascular aging, a geroscience perspective. J Am Coll Cardiol (2020) 75:931–41. doi: 10.1016/j.jacc.2019.11.061

25. Ungvari Z, Tarantini S, Kiss T, Wren JD, Giles CB, Griffin CT, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. Nat Rev Cardiol (2018) 15:555–65. doi: 10.1038/nrcardio.2018.00300

26. van der Heof TP, Echavarria-Pinto M, Meuwissen M, Stegeshows HE, Escaned J, Pieck JJ. Contribution of age-related microvascular dysfunction to abdominal coronary. JACC Cardiovasc Interventions (2020) 13:20–9. doi: 10.1016/j.jcin.2019.08.052

27. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Ciszar A. Mechanisms of vascular aging. Circ Res (2018) 123:849–67. doi: 10.1161/CIRCRESAHA.118.311378

28. Strich D, Karavani G, Edri S, Gillis D. TSH enhancement of FT4 to FT3 conversion is age dependent. Eur J Endocrinol (2017) 176:77–72. doi: 10.1530/EJE-16-0007

29. Wang K, Ojamaa K, Samuelis A, Gilani N, Zhang K, An S, et al. BNP as a new biomarker of cardiac thyroid hormone function. Front Physiol (2020) 11:729. doi: 10.3389/fphys.2020.00729